Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Huyabio International Announces Initiation Of Hbi-3000 Phase 2 Trial
Details : The drug's preclinical and clinical pharmacology supports the potential of HBI-3000 (sulcardine sulfate) to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.
Brand Name : HBI-3000
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2022
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The drug’s preclinical and clinical pharmacology supports the potential of HBI-3000 to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.
Brand Name : HBI-3000
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2022
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000
Details : Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 28, 2020
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?